4D Molecular Therapeutics, Inc. (FDMT)
FDMTNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$12.48
+0.2300 (+1.88%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $689.45m
- P/E
- –
- EPS, last 4 quarters
- $-2.63
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.96 to $16.93
- Average volume
- 980.2k
- Previous close
- $12.25
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $29.50, +136.4% from here
Earnings
next estimate $-1.03Next report
Sep 2025
+1.0%
Dec 2025
+181.1%
Mar 2026
-4.1%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $90.0k | $85.09m | $3.05m | $3.78m |
| Gross profit | $90.0k | $85.09m | $3.05m | $3.78m |
| Operating income | -$61.19m | $14.71m | -$73.62m | -$77.03m |
| Net income | -$56.88m | $19.40m | -$68.76m | -$72.94m |
Last four quarters: revenue $92.01m, margin -194.7%, free cash flow -$155.97m
News
8 latest- Zoetis (ZTS) Q3 Earnings and Revenues Top EstimatesZacks · 5 days ago
- Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should KnowZacks · 6 days ago
- Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue EstimatesZacks · 7 days ago
- 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks · Nov 2, 2026
- 4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene TherapyMarketBeat · Oct 22, 2026
- 4D Molecular Therapeutics Becomes Oversold (FDMT)BNK Invest · Oct 5, 2026
- 4D Molecular Enrolls First Patient In Phase 3 4SIGHT Trial, Reports Durable 2-Year SPECTRA Data RTTNews · Sep 28, 2026
- Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News RTTNews · Aug 17, 2026
The company
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- 4dmoleculartherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.